Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said, ““Ǫ3 FY2c has been a resilient quarter for IOL, marked by double-digit revenue growth, margin expansion, and a 3S% YoY increase in profit before exceptional items and tax, despite prevailing geopolitical uncertainties. This performance underscores the resilience of our operations and sustained demand across our businesses.
Our Pharmaceuticals segment continues to lead growth, delivering an 18% revenue increase year-on-year. Importantly, pharma’s share of overall revenue has risen from 57% in Ǫ3 FY25 to c1% in Ǫ3 FY2c, highlighting its growing contribution. EBIT from Pharmaceuticals grew 32% YoY, driven by healthy volume growth and strong traction in non-Ibuprofen APIs, which are broadening and diversifying our product portfolio.
In Chemicals, we achieved optimal capacity utilisation, reflecting improved demand and operational discipline. EBIT grew 37% YoY, supported by efficiency gains and sustained customer traction. This validates the strength of our diversified business model and the meaningful contribution of both segments.
Looking ahead, our focus remains on expanding our presence in regulated markets, strengthening our new product pipeline, deepening backward integration, and enhancing R&D capabilities. These measures will help us sustain growth momentum, enhance competitiveness, and deliver long-term value creation for our stakeholders.”
